Amersham appoints exec
James E. Rothman has been appointed to the newly created position of chief scientific adviser at Amersham. He has served seven years on the company's scientific advisory board. Rothman will work with CEO William Castell and will sit on Amersham's
James E. Rothman has been appointed to the newly created position of chief scientific adviser at Amersham. He has served seven years on the company's scientific advisory board. Rothman will work with CEO William Castell and will sit on Amersham's Portfolio Committee, which has primary responsibility for recommending overall strategic direction of the company's research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
